Clara Biotech Announces the Closing of its Oversubscribed Seed Financing
Clara Biotech, Inc. (Clara), a Kansas-based biotech start-up creating ground-breaking systems to isolate and purify exosomes, has announced the closing of an oversubscribed seed.
Clara’s scalable system exceeds all alternative isolation methods and can uniquely isolate any exosome sub-type from any biofluid with unmatched purity and quality. The financing to support the company’s initial commercial launch of its ExoRelease Lab Kit™, along with internal scale-up and additional research and development.
"I am delighted at the progress Clara has made since our initial round of funding in 2018. Those pre-seed funds enabled us to hire a stellar team, develop the kit and progress our ability to isolate and purify exosomes. This round will take us to the next level.” said Jim West, CEO of Clara.
“The Company has been extremely capital efficient to date, and we believe the current financing will enable the team to achieve significant milestones and increase its capabilities and staff,” added Joe Gentile, Clara investor.
Clara is leveraging this technology platform to improve exosome isolation and purification for researchers and the exosome industry, helping to unlock future innovations around exosomes.
About Clara Biotech
Clara Biotech was founded in 2018 by James E West III, engineer and entrepreneur, and Dr. Mei He, exosome expert and assistant professor at the University of Florida. Clara Biotech has developed novel methods to isolate and purify exosomes. Its non-chemical ExoRelease™ platform uses proprietary immunocapture and release technology to exclusively isolate exosomes. The ExoRelease™ platform provides a simple, reproducible, time-saving protocol and has the same process for multiple bio-sample types. This yields pure, completely functional, in-tact, and subtyped exosomes. Clara Biotech is in the early stages of commercializing an ExoRelease™ lab kit for Research Use Only.
Please see our recent pitch at BioTools Innovator Accelerator.